StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)

Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –

Acadia Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Acadia Pharmaceuticals's price to book ratio was 2.4× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 2.4× to 14.2×, with a median of 5.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.4×−2.5
2025Dec 31, 20254.9×−0.4
2024Dec 31, 20245.3×−8.9
2023Dec 29, 202314.2×+8.1
2022Dec 30, 20226.1×−0.6
2021Dec 31, 20216.6×−6.4
2020Dec 31, 202013.0×+3.4
2019Dec 31, 20199.5×+0.5
2018Dec 31, 20189.0×−0.7
2017Dec 29, 20179.8×+3.8
2016Dec 30, 20166.0×−9.8
2015Dec 31, 201515.8×+6.2
2014Dec 31, 20149.6×−2.7
2013Dec 31, 201312.3×−2.6
2012Dec 31, 201214.9×+12.9
2011Dec 30, 20112.0×−1.7
2010Dec 31, 20103.7×–

More Acadia Pharmaceuticals figures

See a number that looks wrong?